Novartis to seek approval of Kisqali plus fulvestrant for postmenopausal women with advanced breast cancer
Novartis on Sunday announced positive results from the third Phase III trial of Kisqali in advanced or metastatic breast cancer.
Pharmaceuticals, Biotechnology and Life Sciences
Novartis on Sunday announced positive results from the third Phase III trial of Kisqali in advanced or metastatic breast cancer.
FibroGen, a biopharmaceutical company, on Monday said the results from the Phase 1/2 clinical trial, testing pamrevlumab in combination with…
Celgene Corporation’s study testing Revlimid on patients with previously untreated follicular lymphoma showed that treatment with a chemotherapy-free R2 regimen offered numerically…
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Novartis’s Aimovig…
Celgene Corporation has hired David V. Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO), who will join the…
Sandoz said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Bavarian Nordic has appointed new Chief Financial Officer, coming from a Nasdaq Stockholm exchange listed pharmaceutical company, Orexo AB, it said…
Arix Bioscience’s Non-Executive Director Lord Hutton is stepping down from his position, Arix said Thursday.
Boehringer Ingelheim’s study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency…
Gilead Sciences and Galapagos NV’s Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, has achieved its primary…